Suppr超能文献

经过最大程度药物治疗后慢性鼻窦炎患者的转归。

The fate of chronic rhinosinusitis sufferers after maximal medical therapy.

作者信息

Baguley Campbell, Brownlow Amanda, Yeung Kaye, Pratt Ellie, Sacks Raymond, Harvey Richard

机构信息

Dept of Otolaryngology, Wellington Hospital, Wellington, New Zealand; Applied Medical Research Centre, St. Vincent's Hospital, Sydney, Australia.

出版信息

Int Forum Allergy Rhinol. 2014 Jul;4(7):525-32. doi: 10.1002/alr.21315. Epub 2014 Mar 7.

Abstract

BACKGROUND

Many chronic rhinosinusitis (CRS) treatment regimes revolve around "one-off" maximal medical therapy (MMT) protocols, and although many patients initially respond, long-term control is unpredictable. The value of imaging, endoscopy, and patient progress after MMT for CRS is assessed.

METHODS

Symptomatic CRS patients with computed tomography (CT)-confirmed disease were recruited at a tertiary rhinology clinic. All patients received at least a 3-week oral prednisone course as part of their MMT. Pretreatment and posttreatment nasal symptoms scores (NSS), quality of life (22-item SinoNasal Outcomes Test [SNOT-22]), and CT (Lund-Mackay [LM]) scores were recorded along with post-MMT endoscopy status.

RESULTS

A total of 86 patients (38% female, age 46 ± 13 years) met inclusion criteria. Pre-MMT and post-MMT LM scores were 10.9 ± 5.3 and 8.3 ± 5.5 (change 2.6 ± 3.8, p < 0.001). Median follow-up after their initial post-MMT assessment was 6.3 (interquartile range [IQR] 17) months. At initial post-MMT review, 43 (50%) were symptomatic with persistent radiologic disease ("symptomatic CRS"), 12 (14%) were asymptomatic with no radiologic disease ("resolved CRS"), 21 (24%) were asymptomatic with persistent radiologic disease ("asymptomatic CRS"), and 10 (12%) were symptomatic with no radiologic disease ("alternate diagnosis"). Pre-MMT NSS and SNOT-22 were similar among groups. The "asymptomatic CRS" group had the highest age (52 ± 11 years, p = 0.07). The "alternate diagnosis" group had the lowest initial LM scores (5.2 ± 2.9, p = 0.001). Of the "asymptomatic CRS" patients, 43% relapsed between 3 and 23 months (median 6; IQR 4.4 months) post-MMT and 29% eventually underwent surgery.

CONCLUSION

Although MMT for CRS achieved symptomatic relief in 38% patients, objective evidence of disease was associated with clinical relapse. The concepts of "response" to medical therapy and the need to "control" long-term inflammatory burden need to be balanced.

摘要

背景

许多慢性鼻 - 鼻窦炎(CRS)治疗方案围绕“一次性”最大程度药物治疗(MMT)方案展开,尽管许多患者最初有反应,但长期控制效果难以预测。本研究评估了MMT治疗CRS后影像学、内镜检查及患者病情进展的价值。

方法

在一家三级鼻科诊所招募经计算机断层扫描(CT)确诊的有症状CRS患者。所有患者作为MMT的一部分接受至少为期3周的口服泼尼松疗程。记录治疗前和治疗后的鼻症状评分(NSS)、生活质量(22项鼻鼻窦结局测试[SNOT - 22])、CT(Lund - Mackay [LM])评分以及MMT后的内镜检查情况。

结果

共有86例患者(女性占38%,年龄46±13岁)符合纳入标准。MMT前和MMT后的LM评分分别为10.9±5.3和8.3±5.5(变化2.6±3.8,p<0.001)。首次MMT后评估的中位随访时间为6.3(四分位间距[IQR]17)个月。在首次MMT后复查时,43例(50%)有症状且存在持续性影像学病变(“有症状CRS”),12例(14%)无症状且无影像学病变(“已缓解CRS”),21例(24%)无症状但存在持续性影像学病变(“无症状CRS”),10例(12%)有症状但无影像学病变(“其他诊断”)。各组治疗前NSS和SNOT - 22相似。“无症状CRS”组年龄最大(52±11岁,p = 0.07)。“其他诊断”组初始LM评分最低(5.2±2.9,p = 0.0)。在“无症状CRS”患者中,43%在MMT后3至23个月(中位时间6个月;IQR 4.4个月)复发,29%最终接受了手术。

结论

尽管CRS的MMT使38%的患者症状得到缓解,但疾病的客观证据与临床复发相关。需要平衡药物治疗“反应”的概念和“控制”长期炎症负担的必要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验